trial · primary record
Trastuzumab deruxtecan
Breast Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2031-11-30 |
| Primary endpoint | Objective Response Rate (ORR) |
| Registry ID | NCT07619365 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:23.700Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07619365
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Trastuzumab deruxtecan · compound